Multi-Cancer Early Detection: Hype, Hope, and the Road Ahead
Feb 27, 2025
By Zoran Gatalica, MD, Medical Director, Reference Medicine
Every February, during National Cancer Prevention Month, we are reminded of the critical role that prevention and early detection play in saving lives. While lifestyle changes—such as healthy eating, avoiding tobacco, and regular exercise—are proven strategies to reduce cancer risk, another frontier is emerging: multi-cancer early detection (MCED) testing.
MCED represents a paradigm shift in cancer diagnostics, offering the potential to identify multiple types of cancer through a single, minimally invasive blood test. These tests analyze DNA fragments, proteins, or other biomarkers shed by tumors before symptoms appear, offering a more comprehensive approach and potentially allowing for earlier intervention and better outcomes.
Early detection is the best chance to prevent death from cancer, and MCED could provide us with a new avenue to detect the presence of cancer earlier and less invasively than current standards. The hope is that MCED could become a powerful tool alongside genetic profiling and prevention efforts, ensuring that cancers are caught at their most treatable stage.
But with great potential comes great responsibility. These tests are still in development, and questions about accuracy, validation, and clinical integration remain.
The Promise and Potential of MCED
The novel idea of detecting and addressing cancer through a single drop of blood is thrilling —imagine the potential opportunities to stop cancer in its tracks so easily! It feels like the sky is the limit when we consider the potential advantages of MCED, including:
- Routine screening for asymptomatic individuals
One of the biggest advantages of MCED is its potential to become a routine screening tool, even for people without symptoms. If validated, these tests could be incorporated into annual health check-ups, much like cholesterol tests or blood pressure screenings. This could be a game-changer for early intervention, especially for hard-to-detect cancers like pancreatic, ovarian, and lung cancer.
- Early intervention and improved treatment outcomes
The earlier a cancer is detected, the better the chances of successful treatment, which is why mammography, colonoscopies, and stool sample testing are part of our standard of care today. MCED could make these screenings easier and more widely available and could be particularly effective for “silent killer” cancers, which often go undiagnosed until they are in advanced stages. Instead of waiting for a patient to suffer dramatic weight loss to indicate pancreatic cancer, for example, a single drop of blood could detect cancerous cells that are shedding much earlier in the process, possibly before the patient even shows symptoms.
- Targeting high-risk populations
MCED could be especially valuable for people over a certain age, younger people with a family history of cancer, or those exposed to environmental or occupational risks. For example, a woman who carries a breast cancer susceptibility gene mutation, may start screening at a young age to detect the potential onset of breast cancer. Or a worker in a chemical-laden industry such as oil and gas refineries might have preemptive screening as part of their workforce safety protocol. By prioritizing early detection in high-risk groups, MCED could help catch cancers before they advance, improving survival rates and reducing the need for aggressive treatments – also significantly reducing downstream healthcare costs.
- Integrating genetic risk and early detection
Genetic risk assessment has been revolutionary in helping to assess the possibility of a predisposition to certain types of cancer. Experts emphasize that MCED should not replace genetic risk assessment but rather complement it. A holistic approach that combines genetic risk assessment with real-time detection could provide a more accurate picture of a patient’s cancer risk.
Challenges and Limitations of MCED
There’s always a catch, though. MCED has a long road to travel before it becomes standard of care, and we must take a conservative, cautious, and even skeptical approach as the science continues to develop.
- Clinical validation is essential
MCED is in its infancy in terms of clinical validation and needs to be thoroughly studied before we can champion success. Not only do we need to know if these tests can accurately detect cancer, but whether they can detect it early enough to be of value. This requires large-scale, randomized trials over a long time period.
- Clinical questions
One of the biggest challenges with MCED is ensuring that test results are accurate not only at identifying indications of cancer, but also the absence of cancer, to prevent false positives and false negatives. Furthermore, there may be variability in the types of cancer these tests can detect, as some cancers may not shed enough biomarkers in the early stages. These clinical questions will need to be considered. And importantly, resources must be available to participants to answer the questions that arise from using these tests.
- Regulatory and reimbursement hurdles
If clinically validated, MCED must pass other hurdles – namely regulatory and reimbursement. Not only will the tests need to pass through the complex and lengthy FDA approval process, but they will also need to receive validation from professional societies like the National Cancer Institute and others. They will also require the creation of a new category for reimbursement from CMS and payors in order to be truly usable in practice.
- Access and affordability
If MCED becomes widely available, how can we ensure that the tests are used appropriately? Appropriate training and ongoing support of healthcare providers will be necessary in order to properly inform the participants of risks and benefits for MCED. What will be the cost of these tests? Will payers cover them? How will these issues impact accessibility? These questions will need to be addressed before MCED can become mainstream.
- MCED does not replace prevention
Prevention doesn’t start with MCED. No matter how early the detection or start of the treatment, reducing the risk of getting cancer in the first place is still the most important health policy, and it includes addressing individual lifestyle as well as societal and environmental risk factors.
National Cancer Prevention Month reminds us that prevention remains the most powerful tool in reducing cancer deaths. However, prevention alone is not enough. Despite our best efforts to live healthier lives, cancer can still develop—often silently, until it reaches an advanced stage. That’s where MCED has the potential to change lives.
By integrating MCED with preventive measures, we can create a future where cancer is diagnosed earlier and survival rates improve.
The road ahead is long but promising. With continued research, careful regulatory oversight, and a commitment to combining prevention with innovation in early detection and treatment, MCED could become a game-changer in our fight against cancer.
In the words of biochemist and Nobel Prize winner Albert Szent-Györgyi, “Discovery consists of seeing what everybody has seen and thinking what nobody has thought."
Suggested reading
